Partnering Events:

Cambridge BioMagnetics Limited

T. MitreliasCambridge BioMagnetics Limited, UK

Keywords:pharmaceuticals, biotech

Abstract:Cambridge Biomagnetics (CBM) will commercialise a generic technology for encoding chemical and biological compounds to perform ultra high throughput multiplexed assays with unprecedented speed and reliability. The assays are used in Clinical Diagnostics, Drug Discovery and Genome Sequencing; these are multi-billion dollar markets that show double digit annual growth rates. The company will also provide advanced multi-analyte biosensors to the health care industry by implementing our platform technology that is unique and offers the ability to customise products depending on the applications the end users require. It is a disruptive technology that can replace microarrays and is based on the development of magnetic microlabels that provide billions of unique codes to encode vast numbers of biochemical probes. In addition, the write ability of the technology will be utilised to synthesise and screen extremely large chemical libraries at a cost that is 1000 times less ($0.0001 per probe) than the cost of an assay performed with microarrays. CBM’s near term strategy is to develop a range of biosensors and collaborations with established companies to ensure a revenue stream while in parallel develop more sophisticated products.